Intervening in OSM-OSMR signaling to regulate the iCAF reprogramming process and targeting OSMR to enhance the therapeutic effect of gemcitabine would be novel directions for treating PC (Table 1). The gene discussed is OSMR; the disease is pachyonychia congenita.